RecruitingNCT06258122

Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV

Evolution Over 15 Years (2008-2023) of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV


Sponsor

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

Enrollment

120 participants

Start Date

Apr 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Main objective is: * To characterize the evolution of the immuno-virological profile of circulating blood cells and immune aging in patients who had participated to TEMPO-1 in 2007-2008 * To evaluate the role of immune aging and inflammatory profile in the occurrence of comorbidities in HIV-infected individuals over a 15-year period The alterations that affect the innate and adaptive immune cell compartments in HIV-infected patients are reminiscent of the process of immune aging, characteristic of old age. These alterations, the presumed cause of which is the chronic systemic immune activation established in patients, contribute to the depletion of lymphoid resources which probably leads to the decline of immune competence with the progression of HIV disease. The comparison between HIV-1-infected patients and uninfected older adults goes beyond the mere appearance of immunosenescence and extends to the deterioration of a number of physiological functions linked to inflammation and to systemic aging. By inducing persistent and lasting immune activation, HIV-1 infection is now considered a model of accelerated immunosenescence and systemic aging. During this process, the immune system quickly becomes exhausted, because the source of its exhaustion (i.e. HIV) cannot be eliminated. To determine which factors may contribute to immunosenescence in HIV-1 infection, we propose an extensive immune and virological evaluation in patients who participated in a cross-sectional assessment of immune functions and TEMPO-1 viral reservoirs after 15 years of evolution in order to determine their immune and viral trajectories, to compare these trajectories with the major clinical events and the comorbidities occurring in them.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term follow-up study tracking people living with HIV and a healthy comparison group to understand how HIV infection affects aging and immune health over time. It builds on an earlier study called TEMPO-1. **You may be eligible if...** - You previously participated in the TEMPO-1 study - You are 18 or older - You are either living with HIV or are part of the HIV-negative comparison group - You are enrolled in a social security or health insurance scheme (in France) - You have signed the consent form **You may NOT be eligible if...** - You are under legal protection due to diminished mental or physical capacity ("sauvegarde de justice" or legal guardianship) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Hôpital Pitié-Salpêtrière

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06258122


Related Trials